RSMDF 最新10-Q变化
将 RSMDF 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-30 与上一份 10-Q · 2026-05-01
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +52 | −74 | ~14 | 18 |
| 市场风险(第3项) | 文字有新增/删除 | +10 | −7 | ~13 | 18 |
| 控制与程序 | 文字有新增/删除 | +9 | −7 | ~5 | 15 |
| 法律诉讼 | 文字有新增/删除 | +9 | −7 | ~4 | 13 |
| 风险因素 | 部分风险因素更新 | +9 | −7 | ~3 | 12 |
| 其他信息 | 文字有新增/删除 | +3 | −5 | ~1 | 11 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-30
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software …
On September 1, 2026, we completed the previously announced sale of our MatrixCare business. The transaction was undertaken as part of our portfolio optimization strategy to increase focus on our core growth areas of sleep, breathing, and connected home-based healthcare. The transaction does not rep…
During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expens…
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Net revenue for the three months ended September 30, 2026 was $1.4 billion, an increase of 6% compared to the three months ended September 30, 2025. Gross margin was 61.5% for the three months ended September 30, 2026 compared to 61.2% for the three months ended September 30, 2025. Diluted earnings …
相对上期删除的文字 · 来源:10-Q · 2026-05-01
We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing, or SDB, chronic obstructive pulmonary disease, neuromuscular dise…
Net revenue for the three months ended March 31, 2026 was $1.4 billion, an increase of 11% compared to the three months ended March 31, 2025. Gross margin was 62.2% for the three months ended March 31, 2026 compared to 59.3% for the three months ended March 31, 2025. Diluted earnings per share was $…
At March 31, 2026, our cash and cash equivalents totaled $1.7 billion, our total assets were $8.8 billion and our stockholders’ equity was $6.5 billion.
Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025
Net revenue for the three months ended March 31, 2026 increased to $1,431.4 million from $1,291.7 million for the three months ended March 31, 2025, an increase of $139.7 million or 11% (an 8% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by seg…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-10-30
current levels of gross margin and operating expenses as a percentage of net revenue if we are unable to offset such higher costs through price increases.
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
相对上期删除的文字 · 来源:10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
相对上期删除的文字 · 来源:10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-10-30
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Transition Agreement with Brett Sandercock dated May 6, 2026.
相对上期删除的文字 · 来源:10-Q · 2026-05-01
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
During the quarterly period ended March 31, 2026, none of our directors or executive officers terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (each term as defined in Item 408 of Regulation S-K).
Employment Agreement with Aaron Bloomer dated April 24, 2026
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议